Clinical Trial Update: Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms. [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating Lumateperone (Caplyta) to improve apathy in patients with psychotic symptoms, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psychosis
• Schizophrenia

Drugs mentioned

• Caplyta (lumateperone)

Snippet

Sponsor: Louisiana State University Health Sciences Center Shreveport | Conditions: Apathy, Schizophrenia | Phase 3 | Status: RECRUITING